Stockholm, Sweden – 18 September 2025 — Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical need, announces that the Company’s collaborator, Professor Maura Poli (University of Brescia), has been invited to present our joint research on anemia and chronic kidney disease (CKD) at the 32nd Symposium on Glycosaminoglycans, held 18–20 September 2025 at Villa Vigoni, Loveno di Menaggio, Italy. The symposium is an invitation-only summit for world-leading experts in glycosaminoglycans (GAGs) and their clinical applications.

The presentation builds on new preclinical data showcased by Modus and the Brescia team at EHA 2025 (Milan, 14 June 2025). In a well-established CKD model, sevuparin improved both anemia and kidney status, with reduced expression of fibrosis and injury markers; and the effects were observed both at monotherapy and in combination with erythropoietin (EPO). The results align with sevuparin’s hepcidin-lowering activity and strengthen the rationale for treating CKD with anemia.

Modus is delivering according to plan in its clinical program: Part 1 of the ongoing Phase 2a study in patients with CKD and anemia has been completed. Part 2 of the study, aiming for proof-of-concept, is being prepared to start in Q4 2025. The scientific advances during the year — including new data at BioIron and EHA 2025 — have further strengthened sevuparin’s differentiated mechanism.

Quote, CEO John Öhd:
“With the development of sevuparin, Modus is a pioneer in developing medicines from the unique carbohydrate (sugar)-based group of biomolecules known as glycosaminoglycans (GAGs). Our long-standing research together with leading academic groups shows that sevuparin can modulate key factors that drive inflammation- and iron/hepcidin-dysregulated anemia. Receiving attention at an international GAG summit underscores the molecule’s distinctive profile and clinical potential — and it comes as we move into the next step of our Phase 2 program.”

About the presentation at the GAG Symposium
• Speaker: Prof. Maura Poli (University of Brescia)
• Session: Heparinoids: Challenges and Advances
• Title: Heparin and Heparan Sulfate in Iron Metabolism
• Time: Saturday, 20 September 2025, 11:20–11:40 (Villa Vigoni)

For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments
Modus Therapeutics data to be presented at the 32nd Symposium on Glycosaminoglycans – sevuparin in focus for CKD with anemia

Läs mer på MFN